Welcome to our dedicated page for Kineta news (Ticker: KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Kineta, Inc. (KA) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies. The company's primary asset, KVA12.1, is a VISTA blocking immunotherapy designed to enhance the body's immune response against cancer. Kineta is committed to transforming patients' lives through groundbreaking therapies that target the body's protein homeostasis network.
The proteostasis network is crucial for maintaining the body's natural balance of proteins, protecting against diseases such as Alzheimer's, emphysema, Huntington's disease, and type II diabetes. By developing novel small molecule therapeutics, Kineta aims to control this network, offering potential treatments for various genetic and degenerative disorders.
Kineta's recent achievements include the Phase 1/2 VISTA-101 trial of KVA12.1 in patients with solid cancer tumors, with clinical data announced in March 2024. The company continues to make progress with conference presentations and anticipates future milestones in the first quarter of 2024.
For more information, interested parties can contact:
- Jacques Bouchy, EVP Investor Relations & Business Development: jbouchy@kineta.us
- John Mullaly, LifeSci Advisors, LLC: jmullaly@lifesciadvisors.com
- Bruce Mackle, LifeSci Advisors, LLC: bmackle@lifesciadvisors.com
- General inquiries: info@kineta.us
FAQ
What is the current stock price of Kineta (KA)?
What is the market cap of Kineta (KA)?
What does Kineta, Inc. specialize in?
What is KVA12.1?
What diseases does Kineta aim to treat?
What recent achievements has Kineta made?
How can I contact Kineta, Inc. for more information?
What is the proteostasis network?
What are proteostasis regulators?
What future milestones does Kineta anticipate?
How does Kineta's VISTA blocking immunotherapy work?
Where can I find the latest news about Kineta, Inc.?
